Cancer Family
Mesenchymal Cell Neoplasm
CI-CAN-00000027Explore in graph →
Non-malignant413 active trials10 approved drugs208 evidence items
- NCIt
- C7059
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000027Explore in graph →
Clinical trials
1,848 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01265030 | A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis | completed | Phase 1 / Phase 2 | 9 | MaineHealthOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT02275286 | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients(TRASTS) | recruiting | Phase 1 / Phase 2 | 199 | Grupo Espanol de Investigacion en SarcomasOTHER | 3 | May 31, 2023 |
| NCT02333565 | Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas(CEVOREM) | completed | Phase 2 | 20 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT04071574 | Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility(CS-EOSP-ICSI) | completed | Phase 1 / Phase 2 | 200 | Lebanese UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT04254939 | A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor | completed | Phase 1 / Phase 2 | 65 | CStone PharmaceuticalsINDUSTRY | 1 | Apr 27, 2023 | clinicaltrials |
| NCT02066285 | Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma | completed | Phase 2 | 96 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT02638766 | Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST(REGISTRI) | completed | Phase 2 | 15 | Grupo Espanol de Investigacion en SarcomasOTHER | 3 | Mar 27, 2023 | clinicaltrials |
| NCT04138381 | Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)(SeliGIST) | unknown | Phase 1 / Phase 2 | 30 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer(PIVOT IO 020) | terminated | Phase 1 / Phase 2 | 15 | Bristol-Myers SquibbINDUSTRY | 6 | Mar 24, 2023 | clinicaltrials |
| NCT01330966 | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma | completed | Phase 2 | 47 | Emerald Clinical Inc.INDUSTRY | 2 | Mar 10, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05193188 | A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma | unknown | Phase 2 | 70 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT03273712 | Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | completed | Phase 2 | 39 | University of IowaOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05708391 | Radiotherapy Combined With Realgar-Indigo Naturalis Formula (RIF) in the Treatment of Rhabdomyosarcoma(RMS) in Children | unknown | Phase 2 | 53 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Feb 1, 2023 | clinicaltrials |
| NCT02606461 | Selinexor in Advanced Liposarcoma(SEAL) | completed | Phase 2 / Phase 3 | 342 | Karyopharm Therapeutics IncINDUSTRY | 10 | Jan 23, 2023 | clinicaltrials |
| NCT02712112 | A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs | completed | Phase 2 | 51 | Asan Medical CenterOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT03609424 | PDR001 Plus Imatinib for Metastatic or Unresectable GIST | completed | Phase 1 / Phase 2 | 39 | Asan Medical CenterOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT00543712 | A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g) | terminated | Phase 2 | 15 | Genentech, Inc.INDUSTRY | 2 | Dec 13, 2022 | clinicaltrials |
| NCT05641233 | Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy(FIBROPANC-1) | unknown | Phase 1 / Phase 2 | 33 | Erasmus Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05590572 | A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma | not yet recruiting | Phase 1 / Phase 2 | 148 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 2 | Oct 21, 2022 | clinicaltrials |
| NCT03071874 | Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas | active not recruiting | Phase 2 | 28 | Massachusetts General HospitalOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | terminated | Phase 1 / Phase 2 | 151 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT02880020 | Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 2 | 36 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT03442985 | An Efficacy and Safety Study of Palovarotene for the Treatment of MO(MO-Ped) | terminated | Phase 2 | 193 | Clementia Pharmaceuticals Inc.INDUSTRY | 12 | Aug 1, 2022 | clinicaltrials |
| NCT03245450 | Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Eisai Inc.INDUSTRY | 8 | Jun 28, 2022 | clinicaltrials |
| NCT02831257 | AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas | completed | Phase 2 | 18 | Massachusetts General HospitalOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT02357810 | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas | completed | Phase 2 | 178 | Northwestern UniversityOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT03074318 | Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT02821507 | Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma | completed | Phase 2 | 70 | Leiden University Medical CenterOTHER | 2 | Apr 20, 2022 | clinicaltrials |
| NCT03041701 | Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma | terminated | Phase 1 / Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03966742 | Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis | completed | Phase 2 | 8 | Rabin Medical CenterOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT02050919 | Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma | completed | Phase 2 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 21, 2022 | clinicaltrials |
| NCT02487979 | Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 3 | Jan 18, 2022 | clinicaltrials |
| NCT02452554 | Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma | completed | Phase 2 | 62 | Children's Oncology GroupNETWORK | 1 | Jan 13, 2022 | clinicaltrials |
| NCT05080621 | Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) | withdrawn | Phase 1 / Phase 2 | 0 | Deciphera Pharmaceuticals, LLCINDUSTRY | 0 | Jan 5, 2022 | clinicaltrials |
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT00972335 | Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma | terminated | Phase 2 | 18 | SCRI Development Innovations, LLCOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT02247544 | Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma(TRAVELL) | completed | Phase 2 | 105 | Italian Sarcoma GroupNETWORK | 1 | Nov 1, 2021 | clinicaltrials |
| NCT04933669 | Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors(ZJGIST-01) | recruiting | Phase 2 | 122 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02261207 | Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor | completed | Phase 2 | 17 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT01532687 | Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma | completed | Phase 2 | 54 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT01913652 | Ph II Cabazitaxel DD Liposarcoma | completed | Phase 2 | 42 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Sep 14, 2021 | clinicaltrials |
| NCT02471716 | Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor(FPA008-002) | completed | Phase 1 / Phase 2 | 66 | Five Prime Therapeutics, Inc.INDUSTRY | 6 | Aug 31, 2021 | clinicaltrials |
| NCT04906876 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT02216578 | Ph II CABOGIST in GIST | completed | Phase 2 | 51 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jul 15, 2021 | clinicaltrials |
| NCT01441635 | Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids | completed | Phase 2 | 271 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Jul 13, 2021 | clinicaltrials |
| NCT01275222 | Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors | completed | Phase 1 / Phase 2 | 117 | Novartis PharmaceuticalsINDUSTRY | 4 | Jun 25, 2021 | clinicaltrials |
| NCT04886765 | A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma | unknown | Phase 1 / Phase 2 | 238 | AlaMab Therapeutics (Shanghai) Inc.INDUSTRY | 0 | May 14, 2021 | clinicaltrials |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT01759303 | Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung | terminated | Phase 2 | 12 | Emerald Clinical Inc.INDUSTRY | 1 | Apr 13, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jun 26, 2023source: clinicaltrials